Total outstanding credit card debt is set to hit $1 trillion in 2016, a level not seen since 2008, when the financial crisis was heating up. During the first quarter of 2016, credit card debt stood at $951.6 billion, according to the Federal Reserve, nearing its all-time peak of $1.02 trillion in July 2008. But Brooke McGeehan, a vice president of financial planning at RBC Wealth Management, doesn't think the data suggests another credit crunch is brewing. 'We're in a much different place now than where were in July of 2008,' she said. 'In fact, we've spent the last eight years or so, both on a personal and corporate level, deleveraging balance sheets.' She also said consumer delinquency rates are at historic lows. As for why credit card debt is rising, McGeehan credits an improving labor market and the trend of more shoppers spending at online outlets, such as Amazon (AMZN) . 'The only way to pay online is via credit card,' she said. For those in debt, McGeehan suggests paying more than the minimum payment printed on the statement. 'If you only make the minimum payment, you're only paying the interest,' she said. 'You're not making a dent in the actual debt you have.' TheStreet's Scott Gamm has details from Wall Street.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.